PDCD1 and chronic myelogenous leukemia, BCR-ABL1 positive: When CML is treated with tyrosine kinase inhibitors (TKIs), a target drug for bcr-abl, the PD-1 expression level of CD8+ T cells in the complete hematological response group is significantly lower than that in the control group, chronic phase, and blast phase (22).